meta_analysis
    2023
    High Quality

    Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials

    Lang-Illievich K, Klivinyi C, Rumpold-Seitlinger G, Dorn C, Bornemann-Cimenti H

    Published in Nutrients

    Methodology

    Systematic review and meta-analysis of double-blind randomized controlled trials of oral palmitoylethanolamide in chronic pain

    Key Findings

    Palmitoylethanolamide significantly reduced pain intensity compared with placebo or active comparators, with a favorable adverse event profile

    Conclusions

    PEA appears effective in reducing chronic pain intensity with good tolerability

    Limitations

    Small number of trials, heterogeneous formulations and pain conditions, several industry-linked studies

    Supplements Studied

    PEA
    Compound

    Palmitoylethanolamide significantly reduced pain intensity compared with placebo or active comparators, with a favorable adverse event profile

    Outcomes Measured

    Palmitoylethanolamide significantly reduced pain intensity compared with placebo or active comparators, with a favorable adverse event profile

    Related Health Concerns

    Study Details

    Year:2023
    Sample Size:933
    Quality Score:8/10

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.